You're looking at top-line cost to provide care in a very convoluted market. Take chronic for example, a huge chunk is spent on drug treatment. Incentives to us

You're looking at top-line cost to provide care in a very convoluted market. Take chronic for example, a huge chunk is spent on drug treatment. Incentives to use generics are often misaligned from the needs of the patient. Also, about 10-15% of the $3 trillion is administrative waste (payers). There are a lot of areas that we can save.